Screening families of patients with colorectal cancer for a genetic condition would reduce their risk of developing related cancers, new research has determined.
The first direct comparison of treating nonsquamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival.
JAK inhibitors have been found to halt tumor growth in colorectal cancer with a certain genetic mutation, according to a new study.
Patients with HER2-positive breast cancer that has metastasized demonstrate longer survival outcomes if treated with a combination of pertuzumab, trastuzumab, and chemotherapy.
Patients with lung cancer that have developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival when continued use of the drug with chemotherapy is utilized.
Treatnent with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to phase II trial data.
Addition of the experimental drug cediranib to standard chemotherapy improves tumor shrinkage and adds a modest improvement in progression-free survival for patients with cervical cancer that has recurred after treatment.
A new drug, anamorelin, has been found to improve appetite and body mass in patients with advanced lung cancer who are experiencing cancer anorexia and cachexia.
After failure of platinum-based chemotherapy, the tyrosine kinase inhibitor (TKI) afatinib significantly improved progression-free survival in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
For the group deemed at high risk of developing colorectal cancer, fecal blood tests appear to be a more effective means of screening than colonoscopy.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|